Central America Pharmaceuticals & Healthcare Report

Published 30 July 2015

  • 60 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Central America Pharmaceuticals & Healthcare Report

BMI View: Growing demand for pharmaceuticals, compounded by underdeveloped manufacturing capabilities will ensure commercial opportunities for foreign investors within Central America over the long term. Multinational drugmakers and medical suppliers will also continue to benefit from favourable tax incentives and growing medicine consumption driven by a booming burden of chronic disease. Sluggish economies and political instability will remain problematic, though pharmaceutical and health expenditure will continue to rise throughout the region.

Headline Expenditure Projections

  • Pharmaceuticals: USD3.7bn in 2014 to USD3.9bn in 2015; +5.6%. Our forecast has been maintained since Q 3 15 .

  • Healthcare: USD16.8bn in 2014 to USD17.8bn in 2015; +5.8%. Our forecast has been revised upwards since Q 3 15 due to revised historical data.

Risk/Reward Index

Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q315 Pharmaceutical Risk/Reward Index (RRI), the Americas scores 47 out of 100, below Western Europe (76), Asia Pacific (56), and Central and Eastern Europe (56), but above the Middle East and Africa (43). Of the six Central American countries surveyed Costa Rica's RRI score ranks first at 44.4, followed by Panama (42.8), Guatemala (38.8), Nicaragua (34.3),) Honduras (33.4), and El Salvador 32.6.

Key Trends And Developments

July 2015

  • The Supreme Court of Honduras issued an arrest warrant for National Congress Vice-President Lena Gutierrez and 15 other people in connection with a corruption scandal in the country's healthcare system. The scandal involves alleged embezzlement that cost the Social Security Institute about USD120mn.

June 2015

  • Guatemala's Health Office of the Human Rights Ombudsman announced that the Guatemalan public health system has seen no improvement to its drug and medical supply shortages in recent months. The PDH cited concerns over infrastructure and human resources as contributing factors to...

BMI Industry View
7
SWOT
9
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Central America Pharmaceutical Sales, Historic Data And Forecasts
12
Guatemala
12
Table: Guatemala Pharmaceutical Sales Forecasts
12
Costa Rica
13
Table: Costa Rica Pharmaceutical Sales Forecasts
13
El Salvador
13
Table: El Salvador Pharmaceutical Sales Forecasts
13
Honduras
14
Table: Honduras Pharmaceutical Sales Forecasts
14
Panama
14
Table: Panama Pharmaceutical Sales Forecasts
14
Nicaragua
15
Table: Nicaragua Pharmaceutical Sales Forecasts
15
Healthcare Market Forecast
16
Table: Central America Healthcare Expenditure Trends, Historical Data And Forecasts
18
Guatemala
18
Table: Guatemala Healthcare Expenditure Forecasts
18
Costa Rica
18
Table: Costa Rica Healthcare Expenditure Forecasts
19
El Salvador
19
Table: El Salvador Healthcare Expenditure Forecasts
19
Panama
19
Table: Panama Healthcare Expenditure Forecasts
20
Honduras
20
Table: Honduras Healthcare Expenditure Forecasts
20
Nicaragua
21
Table: Nicaragua Healthcare Expenditure Forecasts
21
Pharmaceutical Trade Forecast
22
Guatemala
24
Table: Guatemala Pharmaceutical Trade Data And Forecasts (USDmn)
24
Costa Rica
24
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (USDmn)
25
El Salvador
25
Table: El Salvador Pharmaceutical Trade Data And Forecasts (USDmn)
25
Panama
25
Table: Panama Pharmaceutical Trade Data And Forecasts (USDmn)
26
Honduras
26
Table: Honduras Pharmaceutical Trade Data And Forecasts (USDmn)
26
Nicaragua
26
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (USDmn)
27
Industry Risk Reward Indices
28
Americas Risk/Reward Index - Q4 2015
28
Central America Risk/Reward Index
33
Rewards
34
Risks
34
Industry Trends And Developments
35
Epidemiology
35
Healthcare Sector
36
Guatemala
37
Costa Rica
37
El Salvador
38
Panama
39
Honduras
40
Nicaragua
41
Clinical Trials
41
Regulatory Development
44
Intellectual Property Regime
44
Costa Rica
45
El Salvador
46
Honduras
46
Nicaragua
47
Guatemala
47
Competitive Landscape
48
Company Profile
49
Ancalmo Internacional
49
Donovan Werke
51
Glossary
53
Methodology
55
Pharmaceutical Expenditure Forecast Model
55
Healthcare Expenditure Forecast Model
55
Notes On Methodology
56
Risk/Reward Index Methodology
57
Index Overview
58
Table: Pharmaceutical Risk/Reward Index Indicators
58
Indicator Weightings
59

The Central America Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Central America Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras, to test other views - a key input for successful budgeting and strategic business planning in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%